NLS Pharmaceutics Ltd - Warrants (25/09/2025) EBIT

NLS Pharmaceutics Ltd - Warrants (25/09/2025) (NLSPW) currently reports a EBIT of $-10M as of June 2025. That compares with $-22M in the prior-year period — up 53.8% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s EBIT history and peer comparisons.

NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s EBIT increased from $-22M to $-10M — a 53.8% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s EBIT of $-10M is lower than the Healthcare sector average of $23B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

NLS Pharmaceutics Ltd - Warrants (25/09/2025) reported $-10M in EBIT as of June 2025. That compares with $-22M in the prior-year period — up 53.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-10M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for NLS Pharmaceutics Ltd - Warrants (25/09/2025), and consider following NLSPW for alerts when major investors trade the stock.